Real‐World Experience With Single Ultra‐Low Dose Rituximab for Remission Induction in Pemphigus
The Journal of Dermatology · 2026-07 · 53 (7) · 1057-1061
DOI: 10.1111/1346-8138.70322 ↗Kurz gefasst
Fachartikel in der Zeitschrift The Journal of Dermatology, online erschienen am 22.05.2026. Verfasst von Yu-Chen Jeng und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Dermatology, National Cheng Kung University Hospital, College of Medicine, National Cheng Kung University, Tainan, Taiwan. Hauptthemen laut MEDLINE: Rituximab, Pemphigus, Immunologic Factors. Die Arbeit nennt 11 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
Standard‐dose rituximab (SDRTX) is the established treatment for pemphigus, but optimization of cost‐effectiveness and safety remains desirable. We retrospectively evaluated the efficacy of a single ultra‐low dose RTX infusion (ULRTX; 100 or 200 mg) for remission induction in 12 patients with mild‐to‐severe pemphigus (median baseline Pemphigus Disease Area Index [PDAI] 29.5). 9 patients (75%) achieved complete remission on minimal therapy (CRMT), and among them 5 (41.7%) subsequently achieved complete remission off therapy (CROT), with a median time to CRMT and CROT of 24 weeks and 61 weeks, respectively. Significant corticosteroid sparing was achieved; 9 of 10 evaluable patients tapered prednisolone to ≤ 5 mg/day within 6 months. Despite the reduced dose of RTX, an overall decline in serum anti‐desmoglein 1 and 3 IgG titers and effective peripheral B‐cell depletion (≤ 1%) occurred in evaluable patients. However, early B‐cell repopulation was observed in one patient who experienced an early relapse. Compared with the standard‐dose group ( n = 8), the ULRTX group demonstrated a favorable safety profile with significantly fewer drug‐related adverse events (0% vs. 37.5%, p = 0.049), while maintaining effective clinical remission. Single‐dose ULRTX appears to be a cost‐efficient and biologically effective induction strategy, supporting a personalized, immunologically guided, on‐demand treatment approach.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Dermatology, National Cheng Kung University Hospital, College of Medicine, National Cheng Kung University, Tainan, Taiwan.
- International Center for Wound Repair and Regeneration, National Cheng Kung University, Tainan, Taiwan.
- Institute of Clinical Medicine, College of Medicine, National Cheng Kung University, Tainan, Taiwan.
ORCID-Profile: Yu-Chen Jeng, Wei-Ting Liu, Chao-Kai Hsu
Zitieren
APA
Jeng, Y. C., Liu, W. T., Hsu, C. K., & Yang, C. C. (2026). Real‐World Experience With Single Ultra‐Low Dose Rituximab for Remission Induction in Pemphigus. The Journal of Dermatology, 53(7), 1057-1061. https://doi.org/10.1111/1346-8138.70322
Vancouver
Jeng YC, Liu WT, Hsu CK, Yang CC. Real‐World Experience With Single Ultra‐Low Dose Rituximab for Remission Induction in Pemphigus. The Journal of Dermatology. 2026;53(7):1057-1061. doi:10.1111/1346-8138.70322
BibTeX
@article{Jeng2026,
author = {Jeng, Yu-Chen and Liu, Wei-Ting and Hsu, Chao-Kai and Yang, Chao-Chun},
title = {Real‐World Experience With Single Ultra‐Low Dose Rituximab for Remission Induction in Pemphigus},
journal = {The Journal of Dermatology},
year = {2026},
volume = {53},
number = {7},
pages = {1057--1061},
doi = {10.1111/1346-8138.70322}
}
EUVIMED